Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J.
Point Therapeutics, Inc., Boston, MA, United States
Search grants from Margaret Uprichard
Search grants from Point Therapeutics, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Pre-disease biomarkers of persistent organic pollutants, immune system, and amyotrophic lateral sclerosis
Metabolomic Signatures Linking ALS to Persistent Organic Pollutant Exposures
Synaptic plasticity in young versus aged visual cortex
Investigating Teachers' Use of Tasks, Discourse, and Technology in High-need School Districts
Research Initiation: Robustness Properties of Multiple Loop Feedback Systems
Recently added grants:
Neuronal exosomes to identify biomarkers and pathology of deployment-related TBI
Mechanisms of Berberine for the Treatment of Non-Alcoholic Fatty Liver Disease
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases
Chemoprotection and imaging for aminoglycoside and chemotherapy toxicities
The Mitochondria As Regulators Of Inflammation In Sepsis
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
5R01FD003021-02
Application #
7128133
Study Section
Special Emphasis Panel (ZFD1-OPD (01))
Program Officer
Ganti, Usha
Project Start
2005-09-30
Project End
2007-06-30
Budget Start
2006-09-30
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
Indirect Cost
Institution
Name
Point Therapeutics, Inc.
Department
Type
DUNS #
829400415
City
Boston
State
MA
Country
United States
Zip Code
02110
Related projects
NIH 2006
R01 FD
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J. / Point Therapeutics, Inc.
NIH 2005
R01 FD
Phase 2 Trial: Talabostat in Chronic Lymphocytic Leukemia
Uprichard, Margaret J. / Point Therapeutics, Inc.
Comments
Be the first to comment on Margaret Uprichard's grant